In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish ...

Hepatitis A is a very contagious liver infection that is common in many parts of the world. Here's more about the vaccine for babies and kids.

The hepatitis B vaccine is one of the very first vaccines your baby will get before she leaves the hospital. This vaccine protects her from a dangerous (but preventable!) liver infection and is given ...

Dynavax Technologies Corp (DVAX) reports record revenue for Heplisav-B, advances in vaccine programs, and strategic financial positioning despite rising R&D costs.

Explore the evolution of vaccine technology from Jenner to mRNA, highlighting India's role in COVID-19 vaccine development.

Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

Dynavax reports record HEPLISAV-B revenue, 26% growth in 2024, and strong 2025 guidance. Insights on shingles vaccine progress & market expansion.

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Hong Kong health authorities have apologised for mistakenly giving pneumococcal vaccines to two children at a health centre ...

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results for the fourth ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...